Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | NOS1 | P29475 | 1/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | GFER | P55789 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856237 | 0.91 | CA1 (0.70) | CA1CA2CA9ALDH1A1MAPT | |
| SCHEMBL6419238 | 0.84 | LMNA (0.61) | ALDH1A1MAPTL3MBTL1CACNA1BLMNA | |
| SCHEMBL10055033 | 0.84 | LMNA (0.61) | ALDH1A1MAPTL3MBTL1CACNA1BLMNA | |
| SCHEMBL26267793 | 0.84 | TAAR1 (0.52) | CA1CA2CA9ALDH1A1MAPT | |
| SCHEMBL855759 | 0.84 | ALDH1A1 (0.62) | CA1CA2CA9ALDH1A1MAPT | |
| SCHEMBL855663 | 0.84 | ALDH1A1 (0.64) | CA1CA2CA9ALDH1A1MAPT | |
| SCHEMBL3067983 | 0.83 | CNR2 (0.71) | ALDH1A1MAPTNPC1L3MBTL1CACNA1B | |
| SCHEMBL2990622 | 0.82 | CA1 (0.65) | CA1CA2CA9ALDH1A1MAPT | |
| SCHEMBL16846471 | 0.82 | CA1 (0.60) | CA1CA2CA9ALDH1A1MAPT | |
| SCHEMBL855496 | 0.82 | AGER (0.61) | CA1CA2CA9ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008073461-A2 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | claimed |
| EP-1308438-B9 | 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-28 | — | — | EP | disclosed |
| EP-1308438-B1 | 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-7105567-B2 | 3-substituted urea derivatives and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-09-12 | — | — | US | disclosed |
| US-20030207939-A1 | Novel 3-substituted urea derivatives and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-06 | — | — | US | disclosed |
| EP-1308438-A1 | 3-SUBSTITUTED UREA DERIVATIVES AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207939-A1 | Novel 3-substituted urea derivatives and medicinal use thereof | C5AR1, C5AR2, C3AR1 | CA1 2217/4885CA2 4353/4885CA9 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.